Description
Key facts
CAS number:1622848-92-3,
Purity:>98%,
Form:SolidSee storage information,
Molecular weight:377.4 Da,
Molecular formula:C20H19N5O3,
PubChem:77108121,
Nature:Synthetic,
Solubility:Soluble in DMSO,
Biochemical name:(S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-1H-1,2,4-triazole-3-carboxamide,
Biological description:A potent and ATP-competitive receptor-interacting protein-1 (RIP1) kinase inhibitor (IC50 = 1 nM).,
Canonical smiles:CN1C2=CC=CC=C2OCC(C1=O)NC(=O)C3=NNC(=N3)CC4=CC=CC=C4,
Isomeric smiles:CN1C2=CC=CC=C2OC[C@@H](C1=O)NC(=O)C3=NNC(=N3)CC4=CC=CC=C4,
InChi:InChI=1S/C20H19N5O3/c1-25-15-9-5-6-10-16(15)28-12-14(20(25)27)21-19(26)18-22-17(23-24-18)11-13-7-3-2-4-8-13/h2-10,14H,11-12H2,1H3,(H,21,26)(H,22,23,24)/t14-/m0/s1,
InChiKey:LYPAFUINURXJSG-AWEZNQCLSA-N,
IUPAC Name:5-benzyl-N-[(3S)-5-methyl-4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-1H-1,2,4-triazole-3-carboxamide
Product details:
This product is manufactured by BioVision, an Abcam company and was previously called B2232 GSK-2982772. B2232-5 is the same size as the 5 mg size of ab286962.
Properties and Storage Information:
Shipped at conditions-Blue Ice, Appropriate long-term storage conditions--20°C, Storage information-Store in the dark, Store under desiccating conditions, This product is air and light sensitive and impurities can occur as a result of air oxidation or due to metabolism by microbes
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The CYP2C9 protein also known as Cytochrome P450 2C9 is a part of the cytochrome P450 family. It has a molecular mass of approximately 55 kDa. This enzyme is highly expressed in the liver and plays an important role in metabolizing a variety of endogenous compounds and xenobiotics. CYP2C9 is involved in oxidative reactions where it catalyzes the insertion of oxygen into organic substrates through electron transfer processes facilitated by heme as a prosthetic group.
Biological function summary
CYP2C9 participates in the metabolism of several drugs like warfarin and phenytoin rendering them into more water-soluble forms for excretion. This enzyme also contributes to the bioactivation of certain pro-drugs. CYP2C9 does not work alone; it often functions as part of a protein complex with other proteins in the endoplasmic reticulum membrane playing an important role in phase I drug metabolism.
Pathways
CYP2C9 is involved significantly in metabolic pathways including the drug metabolism-cytochrome P450 pathway and the arachidonic acid metabolism pathway. It relates closely to other enzymes in the cytochrome P450 family such as CYP2C19 and CYP2C8 due to overlapping substrate specificities and regulatory mechanisms. These enzymes work together to ensure proper metabolic processing of a wide range of substances.
Genetic variations in CYP2C9 are well-linked with altered drug metabolism leading to conditions such as warfarin sensitivity and phenytoin toxicity. Individuals with certain polymorphisms in this gene may experience unusual drug effects or adverse reactions. Additionally CYP2C9 polymorphisms connect with VKORC1 (Vitamin K epoxide reductase complex subunit 1) in affecting drug dosage requirements for anticoagulant therapy.
